PE20050494A1 - Excipientes en vehiculos de suministro de farmacos - Google Patents
Excipientes en vehiculos de suministro de farmacosInfo
- Publication number
- PE20050494A1 PE20050494A1 PE2004001114A PE2004001114A PE20050494A1 PE 20050494 A1 PE20050494 A1 PE 20050494A1 PE 2004001114 A PE2004001114 A PE 2004001114A PE 2004001114 A PE2004001114 A PE 2004001114A PE 20050494 A1 PE20050494 A1 PE 20050494A1
- Authority
- PE
- Peru
- Prior art keywords
- excipients
- drug supply
- compositions
- beneficial agent
- supply vehicles
- Prior art date
Links
- 239000000546 pharmaceutical excipient Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 230000009286 beneficial effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000002265 Human Growth Hormone Human genes 0.000 abstract 1
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 1
- 239000000854 Human Growth Hormone Substances 0.000 abstract 1
- -1 INTERFERED ALPHA-2a Proteins 0.000 abstract 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 abstract 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 abstract 1
- 239000001639 calcium acetate Substances 0.000 abstract 1
- 235000011092 calcium acetate Nutrition 0.000 abstract 1
- 229960005147 calcium acetate Drugs 0.000 abstract 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 abstract 1
- 239000000920 calcium hydroxide Substances 0.000 abstract 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 abstract 1
- 235000011116 calcium hydroxide Nutrition 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000011667 zinc carbonate Substances 0.000 abstract 1
- 229910000010 zinc carbonate Inorganic materials 0.000 abstract 1
- 235000004416 zinc carbonate Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
REFERIDA A COMPOSICIONES QUE COMPRENDEN: A) UN VEHICULO DE GEL TAL COMO UN POLIMERO BASADO EN ACIDO LACTICO DE ENTRE 3000 Y 120000 DE PESO MOLECULAR. B) UN AGENTE BENEFICIOSO TAL COMO HORMONA DE CRECIMIENTO HUMANO, INTERFERON ALFA-2a, EPO, ENTRE OTROS, QUE SE HALLAN DISPERSOS EN EL GEL. C) UN EXCIPIENTE TAL COMO CARBONATO DE ZINC, ACETATO CALCICO, HIDROXIDO CALCICO, ENTRE OTROS; PARA MODULAR LA VELOCIDAD DE LIBERACION Y ESTABILIZAR AL AGENTE BENEFICIOSO. TAMBIEN REFERIDA A METODOS DE ADMINISTRACION DE DICHAS COMPOSICIONES Y DE PREPARACION DE LOS MISMOS
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51997203P | 2003-11-14 | 2003-11-14 | |
US10/985,116 US20050281879A1 (en) | 2003-11-14 | 2004-11-10 | Excipients in drug delivery vehicles |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20050494A1 true PE20050494A1 (es) | 2005-08-24 |
Family
ID=34623114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004001114A PE20050494A1 (es) | 2003-11-14 | 2004-11-12 | Excipientes en vehiculos de suministro de farmacos |
Country Status (14)
Country | Link |
---|---|
US (1) | US20050281879A1 (es) |
EP (1) | EP1691785A4 (es) |
JP (1) | JP2007511516A (es) |
KR (1) | KR20060125748A (es) |
AR (1) | AR046842A1 (es) |
AU (2) | AU2004291077A1 (es) |
BR (1) | BRPI0416032A (es) |
CA (1) | CA2545913C (es) |
IL (1) | IL175601A0 (es) |
MX (1) | MXPA06005464A (es) |
NO (1) | NO20062781L (es) |
PE (1) | PE20050494A1 (es) |
TW (1) | TW200524631A (es) |
WO (1) | WO2005048989A1 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0315304A (pt) * | 2002-11-06 | 2005-08-16 | Alza Corp | Formulações com depósito para liberação controlada |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US20050106214A1 (en) * | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
WO2007003936A1 (en) * | 2005-07-02 | 2007-01-11 | Arecor Limited | Stable aqueous systems comprising proteins |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
AU2013202598B2 (en) * | 2005-09-30 | 2016-06-09 | Durect Corporation | Sustained release small molecule drug formulation |
US8852638B2 (en) * | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
JP5143131B2 (ja) | 2006-05-30 | 2013-02-13 | インターシア セラピューティクス,インコーポレイティド | 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ |
PL2359808T3 (pl) | 2006-08-09 | 2013-10-31 | Intarcia Therapeutics Inc | Osmotyczne systemy dostawcze i zespoły tłokowe |
CA2683610C (en) | 2007-04-23 | 2013-01-08 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
CA2686137C (en) | 2007-05-18 | 2021-01-12 | Durect Corporation | Improved depot formulations |
CA2687979C (en) | 2007-05-25 | 2017-07-04 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of risperidone compounds |
US20110027172A1 (en) * | 2007-12-10 | 2011-02-03 | Zhuang Wang | Drug delivery system for pharmaceuticals and radiation |
DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
US8956642B2 (en) * | 2008-04-18 | 2015-02-17 | Medtronic, Inc. | Bupivacaine formulation in a polyorthoester carrier |
US20100016808A1 (en) * | 2008-07-17 | 2010-01-21 | Bioform Medical, Inc. | Thin-Walled Delivery System |
ES2344674B1 (es) * | 2008-08-07 | 2011-06-29 | Gp Pharm, S.A. | Composicion farmaceutica inyectable de taxanos. |
KR101823699B1 (ko) | 2009-09-28 | 2018-01-30 | 인타르시아 세라퓨틱스 인코포레이티드 | 실질 항정상태 약물 전달의 신속 확립 및/또는 종결 |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
EP2841105A4 (en) * | 2012-03-30 | 2016-12-21 | Nanunanu Ltd | MAGNESIUM PHOSPHATE GELS |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
JP2016503771A (ja) | 2012-12-21 | 2016-02-08 | サノフイ | エキセンジン−4誘導体 |
US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
US9737605B2 (en) | 2013-03-11 | 2017-08-22 | Durect Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
CN105764491A (zh) | 2013-12-09 | 2016-07-13 | 度瑞公司 | 药物活性剂复合物、聚合物复合物,以及包括其的组合物和方法 |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
NZ731309A (en) | 2014-11-07 | 2022-02-25 | Indivior Uk Ltd | Buprenorphine dosing regimens |
KR20230104762A (ko) * | 2015-03-18 | 2023-07-10 | 산텐 세이야꾸 가부시키가이샤 | 서방성 의약 조성물 |
MX2017015504A (es) | 2015-06-03 | 2018-05-15 | Intarcia Therapeutics Inc | Sistemas de colocacion y remoción de implante. |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TWI755356B (zh) * | 2015-07-01 | 2022-02-21 | 日商參天製藥股份有限公司 | 含檸檬酸酯之緩釋劑之用途 |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
CN105295310A (zh) * | 2015-11-11 | 2016-02-03 | 苏州国泰科技发展有限公司 | 一种绿色环保型增塑剂 |
AU2017268161B2 (en) | 2016-05-16 | 2020-03-12 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
AU2018206539A1 (en) | 2017-01-03 | 2019-07-18 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
KR20220140711A (ko) | 2020-01-13 | 2022-10-18 | 듀렉트 코퍼레이션 | 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US630200A (en) * | 1899-03-13 | 1899-08-01 | Draper Co | Warp-stop-motion mechanism. |
US4443340A (en) * | 1981-10-09 | 1984-04-17 | Betz Laboratories, Inc. | Control of iron induced fouling in water systems |
US4985404A (en) * | 1984-10-04 | 1991-01-15 | Monsanto Company | Prolonged release of biologically active polypeptides |
US4853218A (en) * | 1987-02-24 | 1989-08-01 | Schering Corporation | Zinc-protamine-alpha interferon complex |
US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
CA2129514A1 (en) * | 1992-03-12 | 1993-09-16 | M. Amin Khan | Controlled released acth containing microspheres |
US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
US20030035845A1 (en) * | 1992-06-11 | 2003-02-20 | Zale Stephen E. | Composition for sustained release of non-aggregated erythropoietin |
US5711968A (en) * | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
US5242910A (en) * | 1992-10-13 | 1993-09-07 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
EP1013270A3 (en) * | 1992-12-02 | 2001-03-28 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
ES2171186T3 (es) * | 1994-04-08 | 2002-09-01 | Atrix Lab Inc | Composiciones liquidas de difusion. |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US6184227B1 (en) * | 1995-07-21 | 2001-02-06 | Savvipharm Inc. | Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases |
US5801012A (en) * | 1996-09-17 | 1998-09-01 | Northwestern University | Methods and compositions for generating angiostatin |
CA2591581C (en) * | 1996-12-20 | 2013-01-29 | Alza Corporation | Gel composition and methods |
US6113947A (en) * | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
JP3077635B2 (ja) * | 1997-06-20 | 2000-08-14 | 日本電気株式会社 | 高速無線アクセス装置 |
JP2002532210A (ja) * | 1998-12-18 | 2002-10-02 | アンジオソニックス インコーポレイテッド | 超音波により癌および他の細胞増殖性疾病を阻止および治療する方法 |
US20030211974A1 (en) * | 2000-03-21 | 2003-11-13 | Brodbeck Kevin J. | Gel composition and methods |
US20030027833A1 (en) * | 2001-05-07 | 2003-02-06 | Cleary Gary W. | Compositions and delivery systems for administration of a local anesthetic agent |
EP1446100B1 (en) * | 2001-11-14 | 2011-05-04 | Durect Corporation | Injectable depot compositions and uses thereof |
JP2005519873A (ja) * | 2001-11-14 | 2005-07-07 | アルザ・コーポレーション | カテーテル注入可能なデポー組成物およびそれらの使用 |
DE60232987D1 (de) * | 2001-11-14 | 2009-08-27 | Durect Corp | Injizierbare depotzusammensetzungen |
US20040001889A1 (en) * | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
US20050106214A1 (en) * | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
-
2004
- 2004-11-10 US US10/985,116 patent/US20050281879A1/en not_active Abandoned
- 2004-11-12 MX MXPA06005464A patent/MXPA06005464A/es unknown
- 2004-11-12 TW TW093134556A patent/TW200524631A/zh unknown
- 2004-11-12 BR BRPI0416032-0A patent/BRPI0416032A/pt not_active IP Right Cessation
- 2004-11-12 CA CA2545913A patent/CA2545913C/en not_active Expired - Fee Related
- 2004-11-12 JP JP2006539843A patent/JP2007511516A/ja active Pending
- 2004-11-12 AU AU2004291077A patent/AU2004291077A1/en not_active Abandoned
- 2004-11-12 WO PCT/US2004/037606 patent/WO2005048989A1/en active Application Filing
- 2004-11-12 EP EP04819090A patent/EP1691785A4/en not_active Withdrawn
- 2004-11-12 KR KR1020067009218A patent/KR20060125748A/ko not_active Application Discontinuation
- 2004-11-12 PE PE2004001114A patent/PE20050494A1/es not_active Application Discontinuation
- 2004-11-15 AR ARP040104211A patent/AR046842A1/es not_active Application Discontinuation
-
2006
- 2006-05-11 IL IL175601A patent/IL175601A0/en unknown
- 2006-06-14 NO NO20062781A patent/NO20062781L/no not_active Application Discontinuation
-
2011
- 2011-05-02 AU AU2011201972A patent/AU2011201972B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AR046842A1 (es) | 2005-12-28 |
AU2011201972A1 (en) | 2011-05-19 |
CA2545913A1 (en) | 2005-06-02 |
TW200524631A (en) | 2005-08-01 |
CA2545913C (en) | 2013-12-31 |
JP2007511516A (ja) | 2007-05-10 |
BRPI0416032A (pt) | 2007-01-02 |
IL175601A0 (en) | 2006-09-05 |
WO2005048989A1 (en) | 2005-06-02 |
EP1691785A1 (en) | 2006-08-23 |
EP1691785A4 (en) | 2012-08-29 |
NO20062781L (no) | 2006-08-14 |
KR20060125748A (ko) | 2006-12-06 |
AU2011201972B2 (en) | 2013-06-13 |
US20050281879A1 (en) | 2005-12-22 |
MXPA06005464A (es) | 2006-08-11 |
AU2004291077A1 (en) | 2005-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20050494A1 (es) | Excipientes en vehiculos de suministro de farmacos | |
ZA200601385B (en) | Methods for administering aripiprazole | |
BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
BRPI0416590A (pt) | excipientes em veìculos de distribuição de fármacos | |
BRPI0414907A (pt) | formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas | |
NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
MXPA05012791A (es) | Formulacion sostenida que contiene dimeticona. | |
PT1317419E (pt) | Compostos e composições de ácido cianofenoxicarboxílico para administrar agentes activos | |
EA200501819A1 (ru) | Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке | |
AU2001296865A1 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
MXPA05014193A (es) | Fomas de dosis de liberacion sostenida de anestesicos para el manejo del dolor. | |
HK1048801A1 (en) | Phenoxy carboxylic acid compounds and compositions for delivering active agents | |
AU2274201A (en) | Compounds and compositions for delivering active agents | |
AP2001002264A0 (en) | Sustained release formulations for growth hormone secretagogues. | |
TW200806318A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
BR0312007A (pt) | Controle de taxa de administração transcutânea usando composições farmacêuticas amorfas | |
BR0214610A (pt) | Composições poliméricas de liberação controlada de compostos promotores do crescimento ósseo | |
AR011133A1 (es) | MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA. | |
CO5640120A2 (es) | Formulacion y metodods para el tratamiento de trombocitemia | |
IL157841A0 (en) | Activation of natural killer cells by adenosine a3 receptor agonists | |
AR001738A1 (es) | Preparados en forma de capsulas para el tratamiento de plantas y método para administrar compuestos biologicamente activos a plantas | |
UY25192A1 (es) | Formulación medicamentosa con liberación controlada de sustancia activa | |
CA2502731A1 (en) | Sustained release composition for oral administration of drugs | |
WO2004078111A3 (en) | Extended release minocycline compositions and processes for their preparation | |
TW200503785A (en) | Dosage form containing (S)-pantoprazole as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |